Gastroenterology Unit, Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.
Dig Liver Dis. 2010 Apr;42(4):287-90. doi: 10.1016/j.dld.2009.06.007. Epub 2009 Jul 24.
To assess the efficacy and tolerability of Helicobacter pylori first-line treatment (omeprazole-clarithromycin-metronidazole) and second-line rescue option (omeprazole-clarithromycin-levofloxacin) in patients allergic to penicillin.
Prospective multicenter study including consecutive patients allergic to penicillin. Therapy regimens: First-line treatment (50 patients): Omeprazole (20mg b.i.d.), clarithromycin (500 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 7 days. Second-line treatment (15 therapy failures out of the aforementioned 50 patients): Omeprazole (20mg b.i.d.), clarithromycin (500 mg b.i.d.) and levofloxacin (500 mg b.i.d.) for 10 days.
Negative (13)C-urea breath test 8 weeks after completion of treatment.
(1) First-line treatment (omeprazole-clarithromycin-metronidazole): Per-protocol and intention-to-treat eradication rates were 55% (27/49; 95%CI=40-70%) and 54% (27/50; 95%CI=39-69%). Compliance with treatment and follow-up was complete in 98% of cases (one patient was not compliant due to nausea). Adverse events were reported in 5 patients (10%): 4 nausea, 1 diarrhoea. (2) Second-line treatment (omeprazole-clarithromycin-levofloxacin): Per-protocol and intention-to-treat eradication rates were both 73% (11/15; 95%CI=45-92%). Compliance with treatment and follow-up was complete in all the cases. Adverse events were reported in 4 patients (20%), which did not prevent the completion of treatment: Mild nausea (2 patients), and vomiting and myalgias/arthralgias (1 patient).
In H. pylori infected patients allergic to penicillin, the generally recommended first-line treatment with omeprazole, clarithromycin and metronidazole has low efficacy for curing the infection. On the other hand, a levofloxacin-containing regimen (together with omeprazole and clarithromycin) represents an encouraging second-line alternative in the presence of penicillin allergy.
评估对青霉素过敏的患者中幽门螺杆菌一线治疗(奥美拉唑-克拉霉素-甲硝唑)和二线补救选择(奥美拉唑-克拉霉素-左氧氟沙星)的疗效和耐受性。
前瞻性多中心研究,包括对青霉素过敏的连续患者。治疗方案:一线治疗(50 例患者):奥美拉唑(20mg,每日 2 次)、克拉霉素(500mg,每日 2 次)和甲硝唑(500mg,每日 2 次),连用 7 天。二线治疗(上述 50 例患者中有 15 例治疗失败):奥美拉唑(20mg,每日 2 次)、克拉霉素(500mg,每日 2 次)和左氧氟沙星(500mg,每日 2 次),连用 10 天。
治疗完成后 8 周时(13)C-尿素呼气试验阴性。
(1)一线治疗(奥美拉唑-克拉霉素-甲硝唑):按方案和意向治疗根除率分别为 55%(27/49;95%可信区间=40-70%)和 54%(27/50;95%可信区间=39-69%)。98%的病例(1 例因恶心未完全遵守治疗和随访)完全遵守治疗和随访。5 例(10%)报告了不良事件:4 例恶心,1 例腹泻。(2)二线治疗(奥美拉唑-克拉霉素-左氧氟沙星):按方案和意向治疗根除率均为 73%(11/15;95%可信区间=45-92%)。所有病例均完全遵守治疗和随访。4 例(20%)报告了不良事件,但未阻止治疗完成:轻度恶心(2 例),呕吐和肌痛/关节痛(1 例)。
在对青霉素过敏的幽门螺杆菌感染患者中,通常推荐的奥美拉唑、克拉霉素和甲硝唑一线治疗方案治疗感染的疗效较低。另一方面,在存在青霉素过敏的情况下,左氧氟沙星为基础的方案(联合奥美拉唑和克拉霉素)是一种有前途的二线替代方案。